Biological role and clinical implications of homeobox genes in serous epithelial ovarian cancer

Gynecologic Oncology

Volumn 141, Issue 3, 2016, Pages 608-615

  Miller, Katherine R ^a   Patel, Jai N ^a   Ganapathi, Mahrukh K ^a   Tait, David L ^a   Ganapathi, Ram N ^a  

^a LEVINE CANCER INSTITUTE   (United States)

Author keywords

Cancer; Gene; HOX; Ovarian; Protein; Serous

Indexed keywords

HOX PROTEIN;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER PROGNOSIS; CELL INVASION; CELL MIGRATION; DOWN REGULATION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE STRUCTURE; GENE TARGETING; HOX GENE; HUMAN; MOLECULAR DIAGNOSIS; NONHUMAN; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; UPREGULATION; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; HOMEOBOX; NEOPLASM; OVARY TUMOR; PATHOLOGY;

ANIMALS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, HOMEOBOX; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS;

EID: 84961275781     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2016.03.004     Document Type: Review

References (50)

1. Auersperg, N., Wong, A.S.T., Choi, K., Kang, S.K., Leung, P.C.K., Ovarian surface epithelium : biology, endocrinology. Endocr. Rev. 22 (2001), 255–288.
2. Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN. Int. J. Cancer 136:2014 (2012), E359–E386.
3. Tait, D.L., Bahrani-Mostafavi, Z., Vestal, C.G., Richardson, C., Mostafavi, M.T., Downregulation of HOXC6 in serous ovarian cancer. Cancer Investig. 33 (2015), 303–311.
4. Jelovac, D., Armstrong, D.K., Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J. Clin. 61 (2011), 183–203.
5. Kelly, Z.L., Michael, A., Butler-Manuel, S., Pandha, H.S., Morgan, R.G., HOX genes in ovarian cancer. J. Ovarian Res., 4, 2011, 16.
6. Daftary, G.S., Taylor, H.S., Endocrine regulation of HOX genes. Endocr. Rev. 27 (2006), 331–355.
7. Wang, K.C., Helms, J.A., Chang, H.Y., Regeneration, repair and remembering identity: the three Rs of Hox gene expression. Trends Cell Biol. 19 (2009), 268–275.
8. Morgan, R., Hox genes: a continuation of embryonic patterning?. Trends Genet. 22 (2006), 67–69.
9. Shah, N., Sukumar, S., The Hox genes and their roles in oncogenesis. Nat. Rev. Cancer 10 (2010), 361–371.
10. Bhatlekar, S., Fields, J.Z., Boman, B.M., HOX genes and their role in the development of human cancers. J. Mol. Med. (Berl), 2014, 811–823.
11. Gilbert, P.M., Mouw, J.K., Unger, M.A., Lakins, J.N., Gbegnon, M.K., Clemmer, V.B., et al. HOXA9 regulates BRCA1 expression to modulate human breast tumor phenotype. J. Clin. Invest. 120 (2010), 1535–1550.
12. Pojo, M., Gonçalves, C.S., Xavier-Magalhães, A., Oliveira, A.I., Gonçalves, T., Correia, S., et al. A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide. Oncotarget 6 (2015), 7657–7674.
13. Cheng, W., Liu, J., Yoshida, H., Rosen, D., Naora, H., Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat. Med. 11 (2005), 531–537.
14. Yamashita, T., Tazawa, S., Yawei, Z., Katayama, H., Kato, Y., Nishiwaki, K., et al. Suppression of invasive characteristics by antisense introduction of overexpressed HOX genes in ovarian cancer cells. Int. J. Oncol. 28 (2006), 931–938.
15. Santin, A.D., Zhan, F., Bellone, S., Palmieri, M., Cane, S., Bignotti, E., et al. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: Identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int. J. Cancer 112 (2004), 14–25.
16. Naora, H., Yang, Y.Q., Montz, F.J., Seidman, J.D., Kurman, R.J., Roden, R.B., A serologically identified tumor antigen encoded by a homeobox gene promotes growth of ovarian epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 4060–4065.
17. Cantile, M., Franco, R., Tschan, A., Baumhoer, D., Zlobec, I., Schiavo, G., et al. HOX D13 expression across 79 tumor tissue types. Int. J. Cancer 125 (2009), 1532–1541.
18. Bowen, N.J., Walker, L.D., Matyunina, L.V., Logani, S., Totten, K.A., Benigno, B.B., et al. Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells. BMC Med. Genet., 2, 2009, 71.
19. Bonome, T., Lee, J.Y., Park, D.C., Radonovich, M., Pise-Masison, C., Brady, J., et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res. 65 (2005), 10602–10612.
20. Kwon, M.J., Shin, Y.K., Epigenetic regulation of cancer-associated genes in ovarian cancer. Int. J. Mol. Sci. 12 (2011), 983–1008.
21. Cai, L., Abe, M., Izumi, S., Imura, M., Yasugi, T., Ushijima, T., Identification of PRTFDC1 silencing and aberrant promoter methylation of GPR150, ITGA8 and HOXD11 in ovarian cancers. Life Sci. 80 (2007), 1458–1465.
22. Bracken, A.P., Helin, K., Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat. Rev. Cancer 9 (2009), 773–784.
23. Shen, H., Laird, P.W., Interplay between the cancer genome and epigenome. Cell 153 (2013), 38–55.
24. Fiegl, H., Windbichler, G., Mueller-Holzner, E., Goebel, G., Lechner, M., Jacobs, I.J., et al. HOXA11 DNA methylation—a novel prognostic biomarker in ovarian cancer. Int. J. Cancer 123 (2008), 725–729.
25. Karst, A.M., Levanon, K., Drapkin, R., Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 7547–7552.
26. Miao, J., Wang, Z., Provencher, H., Muir, B., Dahiya, S., Carney, E., et al. HOXB13 promotes ovarian cancer progression. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 17093–17098.
27. Ko, S.Y., Ladanyi, A., Lengyel, E., Naora, H., Expression of the homeobox gene HOXA9 in ovarian cancer induces peritoneal macrophages to acquire an M2 tumor-promoting phenotype. Am. J. Pathol. 184 (2014), 271–281.
28. Ko, S.Y., Barengo, N., Ladanyi, A., Lee, J.S., Marini, F., Lengyel, E., et al. HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J. Clin. Invest. 122 (2012), 3603–3617.
29. Klausen, C., Leung, P.C.K., Auersperg, N., Cell motility and spreading are suppressed by HOXA4 in ovarian cancer cells: possible involvement of beta1 integrin. Mol. Cancer Res. 7 (2009), 1425–1437.
30. Ota, T., Klausen, C., Salamanca, M.C., Woo, H.L., Leung, P.C.K., Auersperg, N., Expression and function of HOXA genes in normal and neoplastic ovarian epithelial cells. Differentiation 77 (2009), 162–171.
31. Ko, S.Y., Naora, H., HOXA9 promotes homotypic and heterotypic cell interactions that facilitate ovarian cancer dissemination via its induction of P-cadherin. Mol. Cancer, 13, 2014, 170.
32. Ko, S.Y., Naora, H., Adaptation of ovarian cancer cells to the peritoneal environment: multiple mechanisms of the developmental patterning gene HOXA9. Cancer Cell Microenviron., 1, 2014, E379.
33. Goode, E.L., Chenevix-Trench, G., Song, H., Ramus, S.J., Notaridou, M., Lawrenson, K., et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat. Genet. 42 (2010), 874–879.
34. Ramus, S.J., Antoniou, A.C., Kuchenbaecker, K.B., Soucy, P., Beesley, J., Chen, X., et al. Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Hum. Mutat. 33 (2012), 690–702.
35. Widschwendter, M., Apostolidou, S., Jones, A.A., Fourkala, E.O., Arora, R., Pearce, C.L., et al. HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: a proof of principle study. Int. J. Cancer 125 (2009), 2214–2218.
36. Moss, E.L., Hollingworth, J., Reynolds, T.M., The role of CA125 in clinical practice. J. Clin. Pathol. 58 (2005), 308–312.
37. Badgwell, D., Bast, R.C., Early detection of ovarian cancer. Dis. Markers 23 (2007), 397–410.
38. Tan, H.T., Low, J., Lim, S.G., Chung, M.C.M., Serum autoantibodies as biomarkers for early cancer detection. Febs J. 276 (2009), 6880–6904.
39. Naora, H., Montz, F.J., Chai, C.Y., Roden, R.B., Aberrant expression of homeobox gene HOXA7 is associated with müllerian-like differentiation of epithelial ovarian tumors and the generation of a specific autologous antibody response. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 15209–15214.
40. Stavnes, H.T., Holth, A., Don, T., Kærn, J., Vaksman, O., Reich, R., et al. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival. Gynecol. Oncol. 129 (2013), 358–363.
41. Ota, T., Gilks, C.B., Longacre, T., Leung, P.C.K., Auersperg, N., HOXA7 in epithelial ovarian cancer: interrelationships between differentiation and clinical features. Reprod. Sci. 14 (2007), 605–614.
42. Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2 (2012), 401–404.
43. Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci. Signal., 6, 2013, l1.
44. Bachvarov, D., L'esperance, S., Popa, I., Bachvarova, M., Plante, M., Têtu, B., Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy. Int. J. Oncol. 29 (2006), 919–933.
45. Naora, H., Heterotypic cellular interactions in the ovarian tumor microenvironment: biological significance and therapeutic implications. Front. Oncol., 4, 2014, 18.
46. Stresemann, C., Lyko, F., Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int. J. Cancer 123 (2008), 8–13.
47. Matei, D., Fang, F., Shen, C., Schilder, J., Arnold, A., Zeng, Y., et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 72 (2012), 2197–2205.
48. Fang, F., Munck, J., Tang, J., Taverna, P., Wang, Y., Miller, D.F.B., et al. The Novel, Small-Molecule DNA Methylation Inhibitor SGI-110 as an Ovarian Cancer Chemosensitizer. Clin. Cancer Res., 2014, 1–14.
49. Wang, Y., Cardenas, H., Fang, F., Condello, S., Taverna, P., Segar, M., et al. Epigenetic targeting of ovarian cancer stem cells. Cancer Res. 74 (2014), 4922–4936.
50. Morgan, R., Plowright, L., Harrington, K.J., Michael, A., Pandha, H.S., Targeting HOX and PBX transcription factors in ovarian cancer. BMC Cancer, 10, 2010, 89.